mikeuk/E+ via Getty Images Topline Summary and Update iTeos Therapeutics (NASDAQ:ITOS) is an immunotherapy-focused cancer biotech with an important shot at developing an anti-TIGIT molecule in various forms of cancer. While they have advanced to late-stage clinical study and have significant backing in the form of a GSK partnership, there are numerous headwinds facing their market valuation at this time. In my first analysis of this company, I expressed a "Buy" sentiment with reservations about how ITOS ...